US Stock MarketDetailed Quotes
OCX OncoCyte
- 3.1500
- +0.1300+4.30%
Close Jul 11 16:00 ET
42.10MMarket Cap-596P/E (TTM)
3.1900High2.9300Low53.39KVolume2.9400Open3.0200Pre Close163.64KTurnover0.89%Turnover RatioLossP/E (Static)13.36MShares4.640052wk High3.63P/B18.92MFloat Cap2.080052wk Low--Dividend TTM6.01MShs Float204.8000Historical High--Div YieldTTM8.61%Amplitude2.0800Historical Low3.0650Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
OncoCyte Stock Forum
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
On May 30, 2024, Oncocyte announced that favorable results for its VitaGraft Kidney test were published in the New England Journal of Medicine. Data from a phase 2 study indicated that the test could monitor graft injury and identify responses to the investigational drug felzartamab. Results showed significant reductions in donor-derived cell-free DNA (dd-cfDNA) levels at wee...
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics(ENLV.US)$
$Akebia Therapeutics(AKBA.US)$
$Rekor Systems(REKR.US)$
$OncoCyte(OCX.US)$
No comment yet